Foghorn Therapeutics Inc. announced on May 1, 2025, the election of Neil Gallagher, M.D., Ph.D., and Stuart Duty to its Board of Directors. These appointments are expected to bring decades of deep and multifaceted understanding of the biotechnology industry to Foghorn's strategic leadership.
Dr. Gallagher brings over 20 years of experience leading drug development programs across several therapeutic areas, including oncology, at major pharmaceutical and biopharmaceutical organizations. He currently serves as President, Head of Research and Development at Syndax Pharmaceuticals, and previously held clinical development roles at AbbVie and Novartis Oncology.
Mr. Duty contributes over 30 years of experience in finance and investment banking within the biotechnology and specialty pharmaceuticals sectors. He most recently served as a Senior Managing Director at Guggenheim Securities, LLC, advising on financing activities and strategic transactions. His expertise will be crucial in maximizing Foghorn’s clinical and preclinical pipeline.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.